FEB 2, 2021 ，

Movano正在开发一种用于测量血糖、血压和心率的可穿戴设备，该公司周二向美国证券交易委员会（SEC）提交了一份高达4100万美元的首次公开发行（IPO）申请。
Movano 正在开发一个使用射频 （RF） 技术的专有平台，它相信该技术将实现低成本和可扩展的传感器，这些传感器足够小，可以适应可穿戴
设备。该平台是其开发中的第一个产品的基础，一种非侵入性穿戴设备，旨在将连续葡萄糖监测仪和无袖血压监测器的功能相结合。该公司目前计划在2021年2月对FDA510（k）的通关进行关键试验。莫瓦诺迄今尚未产生任何收入。
总部位于加州的普莱森顿公司成立于2018年，并计划以"MOVE"为标志在纳斯达克上市。Movano 于2020年6月30日秘密提交。National Securities是这笔交易的唯一账簿管理人。未披露定价条款。

Movano, which is developing a wearable device for measuring glucose, blood pressure, and heart rate, filed on Tuesday with the SEC to raise up to $41 million in an initial public offering.

Movano is developing a proprietary platform that uses radio frequency (RF) technology, which it believes will enable the creation of low-cost and scalable sensors that are small enough to fit into a wearable device. The platform is the foundation for its first product in development, a non-invasive and cuffless wearable intended to combine the functionality of a continuous glucose monitor and a cuffless RF-based blood pressure monitor. The company currently plans to conduct pivotal trials for FDA 510(k) clearance in the 2H21. Movano has not generated any revenue to date.

The Pleasanton, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol MOVE. Movano filed confidentially on June 30, 2020. National Securities is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Glucose monitoring device developer Movano files for a $41 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.